press release for the quarter and year ended on 31st March 2025
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
RPG Life Sciences reported strong Q4 FY25 results with revenue from operations rising 13% year-on-year to Rs. 143.09 crores, while profit before tax (before exceptional items) jumped 41% YoY to Rs. 25.00 crores. For the full year FY25, revenue grew 12% YoY to Rs. 653.43 crores and PBT before exceptional items surged 28% YoY to Rs. 150.28 crores. EBITDA margin expanded notably from 23.3% to 26.4% on a full-year basis, marking the sixth consecutive year of margin improvement. The company has built a cash surplus of about Rs. 168 crores from operations, augmented to around Rs. 266 crores after monetising surplus vacant leasehold land at its Navi Mumbai plant. The Board has recommended its highest-ever dividend of 250% plus a special dividend of 50% on a face value of Rs. 8, subject to shareholder approval.
The double-digit revenue growth, expanding margins, and rising profits signal strong operational momentum, likely to support positive investor sentiment. The record dividend payout and sizeable cash pile earmarked for inorganic growth add further upside potential for shareholders.